Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO Pharma Limited has announced a public offering of 625,000 American Depositary Shares (ADSs) at $4.00 each, expected to raise approximately $2,500,000. An additional 93,750 ADSs may be purchased by underwriters to cover over-allotments. The offering is set to close on May 19, 2022, pending customary conditions. Proceeds will fund the IND filing for OK-101 targeting Dry Eye Disease (DED) and support an initial Phase 2 clinical trial. The ADSs will begin trading on Nasdaq under the symbol ‘OKYO’ from May 17, 2022.